This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Phyllis Q. Edwards, MD
Center for Disease Control Atlanta

JAMA. 1975;231(13):1341.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The question of the potential carcinogenicity of isoniazid, raised by Dr. Carolyn T. Miller of the University of Ottawa (230:1254, 1974), is of serious concern. Dr. Miller has kindly agreed to make her data available to the Center for Disease Control for careful study by our staff.

Meanwhile, we are reviewing the current status of persons who had isoniazid for preventive therapy some years ago in studies conducted by the Public Health Service. We have kept up a periodic review of long-term results, not only of the continued effectiveness of preventive treatment in tuberculosis, but also for any indication that there might be delayed adverse effects, such as cancer. To now, we have seen no indication of a carcinogenic effect.

Tuberculosis mortality and morbidity continue to decline, and we hope to see that decline accelerated in the coming years with vigorous application of effective chemotherapy for those who . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?